Form 4: Cidara CFO Karbe's Tax-Related Stock Sale

Cidara Therapeutics' CFO, Frank Karbe, reported the disposition of 7,290 common shares for tax withholding on December 10, 2025, alongside an ESPP acquisition.

Summary

• Frank Karbe, Chief Financial Officer of Cidara Therapeutics, Inc. (CDTX), reported a transaction involving the company's common stock.
• On December 10, 2025, Karbe disposed of 7,290 shares of common stock at a price of $219.6 per share.
• This disposition was identified as shares withheld for taxes related to the vesting of Restricted Stock Units (RSUs).
• Following this transaction, Karbe directly beneficially owns 50,562 shares of Cidara Therapeutics common stock.
• The reported beneficial ownership also includes 352 shares acquired on November 20, 2025, through the Issuer's Employee Stock Purchase Plan (ESPP).

Sentiment

Score: 6

Explanation: The transaction is largely neutral as it primarily involves shares withheld for tax purposes, a routine event. The simultaneous acquisition of shares via ESPP adds a minor positive note, indicating continued employee investment.

Positives

• Acquisition of 352 shares through the Employee Stock Purchase Plan (ESPP) on November 20, 2025, indicates continued participation in employee ownership programs.

Negatives

• Disposition of 7,290 shares of common stock, even for tax purposes, reduces the direct beneficial ownership of the Chief Financial Officer.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine insider filing and is unlikely to have a significant direct impact on shareholder value or perception. The disposal for tax purposes is a common practice and not indicative of a lack of confidence.
• Employees: The CFO's participation in the ESPP could be seen as a positive signal regarding employee benefits and alignment of interests.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CFO disposed of shares to cover tax obligations related to RSU vesting, a common practice that does not typically signal a change in management's outlook or company fundamentals. The simultaneous acquisition of shares through an ESPP indicates continued participation in employee ownership. As such, this filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, which would typically be based on broader financial performance, strategic developments, or market conditions.

Keywords

Cidara Therapeutics, CDTX, Frank Karbe, CFO, Insider Trading, Form 4, Stock Sale, RSU Vesting, Employee Stock Purchase Plan, ESPP, Common Stock